摘要
In recent years,growth hormone and insulin-like growth factors have become key regulators of bone metabolism and remodeling,crucial for maintaining healthy bone mass throughout life.Studies have shown that adult growth hormone deficiency leads to alterations in bone remodeling,significantly affecting bone microarchitecture and increasing fracture risk.Although recombinant human growth hormone replacement therapy can mitigate these adverse effects,improving bone density,and reduce fracture risk,its effectiveness in treating osteoporosis,especially in adults with established growth hormone deficiency,seems limited.Bisphosphonates inhibit bone resorption by targeting farnesyl pyrophosphate synthase in osteoclasts,and clinical trials have confirmed their efficacy in improving osteoporosis.Therefore,for adult growth hormone deficiency patients with osteoporosis,the use of bisphosphonates alongside growth hormone replacement therapy is recommended.
近年来,生长激素和胰岛素样生长因子已成为骨代谢和重塑的关键调节剂,对于生命各阶段健康骨量的维持均至关重要。研究表明,成人生长激素缺乏会引发骨重塑变化,显著改变骨微结构并增加骨折风险。虽然重组人生长激素替代疗法可以减轻这些负面影响,提高骨密度并降低骨折风险,但其治疗骨质疏松症的效果,特别是对于已有生长激素缺乏症的成年人,似乎有限。双膦酸盐通过抑制破骨细胞中的法尼醇焦磷酸合酶起抗骨吸收的作用,临床试验已证实其可有效改善骨质疏松。因此,对患有骨质疏松的成人生长激素缺乏症患者,建议在使用生长激素替代疗法的同时使用双膦酸盐。
出处
《中南大学学报（医学版）》
CAS
CSCD
北大核心
2024年第6期839-847,共9页
Journal of Central South University ：Medical Science
基金
This work was supported by the Special Project of Performance Incentive and Guidance for Scientific Research Institutions of Chongqing,China (jxyn2022-5)。
